Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Authors

Eduard J. van Beers (ORCID: https://orcid.org/0000-0002-3934-7189)
Joline L. Saes (ORCID: https://orcid.org/0000-0003-3219-4981)
M. Van Dijk
Marije Bartels (ORCID: https://orcid.org/0000-0001-9685-1755)
Santosh L. Saraf (ORCID: https://orcid.org/0000-0002-8584-4194)
Cleo Derichs
Erfan NUR
Anita W. Rijneveld (ORCID: https://orcid.org/0000-0003-4715-6750)
Marjon Cnossen
Geoffrey Z.L. Kuppens
Bart J. Biemond
Maria Armila D. Ruiz
Minke A.E. Rab

Institutions

Utrecht University (NL)
Erasmus MC (NL)
University Medical Center (US)
University Medical Center Utrecht (NL)
University of Illinois Chicago (US)
University of Illinois Hospital & Health Sciences System (US)
Erasmus MC - Sophia Children’s Hospital (NL)
University of Amsterdam (NL)

Publication Details

Journal: Haematologica
Published: 2026-02-26
DOI: https://doi.org/10.3324/haematol.2025.289105
Primary Topic: Hemoglobinopathies and Related Disorders
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer
Sanofi
Biogen
Celgene
CSL Behring
Baxalta
Agios Pharmaceuticals
ZonMw
Novo Nordisk
Innovatiefonds Zorgverzekeraars
Swedish Orphan Biovitrum
Nordic Pharma Group

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Eduard J. van Beers, Joline L. Saes, M. Van Dijk, Marije Bartels et al.

Feb 26, 2026

Haematologica

Hemoglobinopathies and Related Disorders

article

Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study

Eduard J. van Beers, Joline L. Saes, M. Van Dijk, Marije Bartels, Santosh L. Saraf, Cleo Derichs, Erfan NUR, Anita W. Rijneveld, Marjon Cnossen, Geoffrey Z.L. Kuppens, Bart J. Biemond, Maria Armila D. Ruiz, Minke A.E. Rab

February 26, 2026article en

Abstract

No abstract available for this paper.

Haematologica

Utrecht University (NL), Erasmus MC (NL), University Medical Center (US), University Medical Center Utrecht (NL), University of Illinois Chicago (US), University of Illinois Hospital & Health Sciences System (US), Erasmus MC - Sophia Children’s Hospital (NL), University of Amsterdam (NL)

Pfizer, Sanofi, Biogen, Celgene, CSL Behring, Baxalta, Agios Pharmaceuticals, ZonMw, Novo Nordisk, Innovatiefonds Zorgverzekeraars, Swedish Orphan Biovitrum, Nordic Pharma Group

Good health and well-being

Openalex Percentile: Top 43%

Hemoglobinopathies and Related Disorders

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.